Abstract: A technique facilitates a well operation employing at least one dehydration tube. The at least one dehydration tube is located along an exterior of a plurality of screen assemblies deployed in a wellbore and is fluidly coupled to a base pipe of at least one of the screen assemblies. The fluid coupling provides fluid access to the base pipe through a base pipe opening. Fluid flow along the at least one dehydration tube is controlled with a flow control mechanism. Additionally, an inflow of fluid from an exterior to an interior of select screen assemblies is separately controlled with an inflow control device associated with each select screen assembly.

Abstract: The design, modeling, synthesis, biological evaluation, and photoaffinity labeling studies of a series of photoreactive potent and selective HDACs 1 and 2 benzamide based probes are disclosed herein.

Abstract: A completion assembly is run downhole into a well. The assembly includes a valve and a material that is adapted to initially configure the valve to prevent fluid flow through the valve in at least one direction. The technique includes performing a downhole completion operation in the well and disintegrating the material to allow the prevented fluid flow through a nozzle of the valve. The nozzle is used to regulate production or injection in the well.

Abstract: A technique facilitates a well operation employing at least one dehydration tube. The at least one dehydration tube is located along an exterior of a plurality of screen assemblies deployed in a wellbore and is fluidly coupled to a base pipe of at least one of the screen assemblies. The fluid coupling provides fluid access to the base pipe through a base pipe opening. Fluid flow along the at least one dehydration tube is controlled with a flow control mechanism. Additionally, an inflow of fluid from an exterior to an interior of select screen assemblies is separately controlled with an inflow control device associated with each select screen assembly.

Abstract: The design, modeling, synthesis, biological evaluation, and photoaffinity labeling studies of a series of photoreactive potent and selective HDACs 1 and 2 benzamide based probes are disclosed herein.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising an HDAC inhibitor of the invention.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: A technique includes running a completion assembly downhole into a well. The assembly includes a valve and a material that is adapted to initially configure the valve to prevent fluid flow through the valve in at least one direction. The technique includes performing a downhole completion operation in the well and disintegrating the material to allow the prevented fluid flow through a nozzle of the valve. The nozzle is used to regulate production or injection in the well.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising a an HDAC inhibitor of the invention.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.